KR20070091609A - 세포외 기질을 표적화하기 위한 조영제 - Google Patents

세포외 기질을 표적화하기 위한 조영제 Download PDF

Info

Publication number
KR20070091609A
KR20070091609A KR1020077011496A KR20077011496A KR20070091609A KR 20070091609 A KR20070091609 A KR 20070091609A KR 1020077011496 A KR1020077011496 A KR 1020077011496A KR 20077011496 A KR20077011496 A KR 20077011496A KR 20070091609 A KR20070091609 A KR 20070091609A
Authority
KR
South Korea
Prior art keywords
contrast agent
formula
residue
residues
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020077011496A
Other languages
English (en)
Korean (ko)
Inventor
다그핀 뢰브하우그
모르텐 에릭센
헤게 베. 피예르딩스타드
앤드류 힐리
Original Assignee
지이 헬스케어 에이에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 지이 헬스케어 에이에스 filed Critical 지이 헬스케어 에이에스
Publication of KR20070091609A publication Critical patent/KR20070091609A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Steroid Compounds (AREA)
KR1020077011496A 2004-11-22 2005-11-21 세포외 기질을 표적화하기 위한 조영제 Withdrawn KR20070091609A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NO20045081 2004-11-22
NO20045081 2004-11-22

Publications (1)

Publication Number Publication Date
KR20070091609A true KR20070091609A (ko) 2007-09-11

Family

ID=36182407

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077011496A Withdrawn KR20070091609A (ko) 2004-11-22 2005-11-21 세포외 기질을 표적화하기 위한 조영제

Country Status (17)

Country Link
US (1) US8182790B2 (https=)
EP (2) EP2243496A3 (https=)
JP (2) JP5116480B2 (https=)
KR (1) KR20070091609A (https=)
CN (1) CN101107016B (https=)
AT (1) ATE494913T1 (https=)
AU (1) AU2005307195A1 (https=)
BR (1) BRPI0518328A2 (https=)
CA (1) CA2586621A1 (https=)
DE (1) DE602005025911D1 (https=)
ES (1) ES2358745T3 (https=)
IL (1) IL182898A0 (https=)
MX (1) MX2007006050A (https=)
NO (1) NO20073039L (https=)
RU (1) RU2007118385A (https=)
WO (1) WO2006054904A2 (https=)
ZA (1) ZA200705043B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011049405A3 (ko) * 2009-10-22 2011-09-29 경북대학교 산학협력단 광학영상 조영제, 그 용도 및 장치

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0610395D0 (en) * 2006-05-25 2006-07-05 Ge Healthcare Ltd Novel imaging agents
EP2056886A2 (en) * 2006-08-28 2009-05-13 GE Healthcare Limited 68ga-labeled peptide-based radiopharmaceuticals
JP2008266194A (ja) * 2007-04-19 2008-11-06 Hiroshi Tanaka 分子プローブの原料として有用な新規有機化合物
GB0722650D0 (en) * 2007-11-19 2007-12-27 Ge Healthcare Ltd Novel imaging method
JP5604305B2 (ja) 2007-12-13 2014-10-08 アンセルム（アンスチチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル） 線維症の非侵襲性の特異的イメージングのための、ポリペプチド、環状ポリペプチドおよびそれを含む医薬
US8815214B2 (en) * 2008-01-18 2014-08-26 Visen Medical, Inc. Fluorescent imaging agents
CN102088991A (zh) 2008-05-13 2011-06-08 堪萨斯大学 金属提取肽标签和相关方法
GB0814722D0 (en) * 2008-08-12 2008-09-17 Ge Healthcare Ltd Treatment monitoring
GB0910013D0 (en) * 2009-06-10 2009-07-22 Ge Healthcare Ltd PET imaging of fibogenesis
CN102504603B (zh) * 2011-10-20 2014-01-29 中国海洋大学 一种多聚物与生物染色剂的偶合物及其制备方法和用途
US9187735B2 (en) 2012-06-01 2015-11-17 University Of Kansas Metal abstraction peptide with superoxide dismutase activity
WO2015085005A1 (en) * 2013-12-03 2015-06-11 The General Hospital Corporation Molecular imaging probes
CN117623996B (zh) * 2022-08-10 2025-07-22 中国药科大学 一种二价keap1-nrf2抑制剂、制备方法及其医药用途

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647447A (en) 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4615876A (en) * 1983-04-25 1986-10-07 Curators Of The University Of Missouri Macrocyclic complexes of technetium-99m for use as diagnostic radionuclides
US4687659A (en) 1984-11-13 1987-08-18 Salutar, Inc. Diamide-DTPA-paramagnetic contrast agents for MR imaging
US5268486A (en) 1986-04-18 1993-12-07 Carnegie-Mellon Unversity Method for labeling and detecting materials employing arylsulfonate cyanine dyes
US6048982A (en) 1986-04-18 2000-04-11 Carnegie Mellon University Cyanine dyes as labeling reagents for detection of biological and other materials by luminescence methods
ATE145337T1 (de) 1988-05-02 1996-12-15 Phanos Tech Inc Verbindungen, zusammensetzungen und verfahren zum binden von bio-affektions-substanzen an oberflächenmembranen von bioteilchen
GB8903022D0 (en) * 1989-02-10 1989-03-30 Celltech Ltd Chemical compounds
EP0643706A1 (en) 1991-11-27 1995-03-22 Zynaxis Inc. Compounds, compositions and methods for binding bio-affecting substances to surface membranes of bio-particles
DE69735901T2 (de) 1996-10-28 2007-05-10 Ge Healthcare As Verbesseringen an oder in verbindung mit diagnostischen/therapeutischen mitteln
ATE314097T1 (de) 1996-10-28 2006-01-15 Amersham Health As Kontrastmittel
JP2001509796A (ja) * 1997-01-29 2001-07-24 ニユコメド・イメージング・アクシエセルカペト 重合体
EP1037947B1 (en) 1997-07-28 2003-09-10 Amersham plc Cyanine dyes
US5942637A (en) * 1998-03-30 1999-08-24 North Dakota State University Research Foundation Compounds containing tetradecachlorocyclohexasilane dianion
US6852318B1 (en) * 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
WO1999058139A2 (en) * 1998-05-08 1999-11-18 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
JP2000095758A (ja) * 1998-09-18 2000-04-04 Schering Ag 近赤外蛍光造影剤および蛍光造影方法
US6230777B1 (en) 1999-02-04 2001-05-15 Midmac Systems, Inc. Filter forming and joining apparatus
CA2405469C (en) * 2000-04-12 2012-03-20 Amersham Health As Integrin binding peptide derivatives
NO20004795D0 (no) * 2000-09-26 2000-09-26 Nycomed Imaging As Peptidbaserte forbindelser
EP1337278A2 (en) * 2000-11-27 2003-08-27 Bristol-Myers Squibb Medical Imaging, Inc. Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent
BRPI0210886B8 (pt) * 2001-07-10 2021-05-25 Amersham Health As composto, composição farmacêutica, uso de um composto, e, métodos de geração de imagens, de monitoração do efeito do tratamento de um corpo humano ou animal com uma droga para combater uma condição associada com câncer e de tratamento de câncer ou de uma doença relacionada em um corpo humano ou animal
GB0116815D0 (en) 2001-07-10 2001-08-29 Nycomed Amersham Plc Improved chelator conjugates
GB0206750D0 (en) 2002-03-22 2002-05-01 Amersham Plc Radiofluorination methods
JP2006510576A (ja) 2002-06-17 2006-03-30 カルテラ、アクチボラグ アテローム性動脈硬化症のプラーク形成の進行を防止するためのインテグリンα１０鎖の方法および使用
US7063158B2 (en) 2003-06-16 2006-06-20 Deepwater Technologies, Inc. Bottom tensioned offshore oil well production riser
NO20033115D0 (no) * 2003-07-08 2003-07-08 Amersham Health As Peptid-baserte forbindelser
GB0317815D0 (en) 2003-07-30 2003-09-03 Amersham Health As Imaging agents
WO2005019247A2 (en) 2003-08-15 2005-03-03 Board Of Regents, The University Of Texas System Cyclic peptide and imaging compound compositions and uses for targeted imaging and therapy
JP2007512321A (ja) * 2003-11-24 2007-05-17 ジーイー・ヘルスケア・アクスイェ・セルスカプ 造影剤
ATE447417T1 (de) * 2004-03-04 2009-11-15 Ge Healthcare As Konjugate von angiotensin-peptid analoga und chelatbildner für diagnose und therapie
RU2393167C2 (ru) * 2004-06-16 2010-06-27 Джи-И Хелткер АС Пептидные соединения
JP5280682B2 (ja) * 2004-06-16 2013-09-04 ジーイー・ヘルスケア・アクスイェ・セルスカプ ペプチド系化合物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011049405A3 (ko) * 2009-10-22 2011-09-29 경북대학교 산학협력단 광학영상 조영제, 그 용도 및 장치

Also Published As

Publication number Publication date
EP1814598A2 (en) 2007-08-08
EP2243496A2 (en) 2010-10-27
MX2007006050A (es) 2007-11-14
JP5116480B2 (ja) 2013-01-09
EP1814598B1 (en) 2011-01-12
WO2006054904A2 (en) 2006-05-26
NO20073039L (no) 2007-08-16
JP2008520658A (ja) 2008-06-19
US8182790B2 (en) 2012-05-22
ATE494913T1 (de) 2011-01-15
IL182898A0 (en) 2007-08-19
EP2243496A3 (en) 2012-12-26
ZA200705043B (en) 2008-09-25
CA2586621A1 (en) 2006-05-26
BRPI0518328A2 (pt) 2008-11-11
DE602005025911D1 (de) 2011-02-24
US20090208412A1 (en) 2009-08-20
WO2006054904A3 (en) 2007-04-05
JP2012207027A (ja) 2012-10-25
ES2358745T3 (es) 2011-05-13
AU2005307195A1 (en) 2006-05-26
RU2007118385A (ru) 2008-12-27
CN101107016A (zh) 2008-01-16
CN101107016B (zh) 2011-11-16

Similar Documents

Publication Publication Date Title
JP2012207027A (ja) 造影剤
US9119885B2 (en) RGD-containing peptidomimetics and uses thereof
JP5043271B2 (ja) ペプチドベースの化合物
RU2394837C2 (ru) Контрастный агент, нацеленный на рецептор урокиназного активатора плазминогена
JP2010513476A (ja) 造影剤
JP5280682B2 (ja) ペプチド系化合物
JP2007510643A (ja) 医薬化合物
RU2505316C2 (ru) Способ визуализации
JP5604305B2 (ja) 線維症の非侵襲性の特異的イメージングのための、ポリペプチド、環状ポリペプチドおよびそれを含む医薬
CN115819525A (zh) 一种靶向肿瘤的伤寒毒素b亚基模拟肽及其应用

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20070521

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid